Lacticaseibacillus paracasei 36 attenuates D-GalN/LPS-induced acute liver injury in mice via suppressing the TLR4/NF-κB/MAPK pathway and NLRP3 inflammasome activation through modulating the intestinal
3 hours ago
- #Gut-liver axis
- #Probiotics
- #Acute liver injury
- Lacticaseibacillus paracasei 36 attenuates D-GalN/LPS-induced acute liver injury (ALI) in mice.
- Mechanism involves suppression of the TLR4/NF-κB/MAPK pathway and NLRP3 inflammasome activation.
- L. paracasei 36 modulates intestinal microbiota, increasing beneficial genera (Ligilactobacillus, Akkermansia) and reducing harmful ones (Alistipes, Parasutterella).
- Pretreatment with L. paracasei 36 reduces serum AST, ALT, and TBil levels, alleviates histopathological damage, and decreases oxidative stress and inflammatory cytokines.
- Multi-omics analysis shows suppression of NF-κB/MAPK pathways and an increase in hepatoprotective metabolites like berberine and flavin nucleotides.
- L. paracasei 36 represents a potential therapeutic strategy for ALI by mitigating inflammation, oxidative damage, apoptosis, and restoring intestinal microbiota homeostasis.